Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Co-registering Cardiac Tissue and Electrophysiology
2026-11-19
A proof-of-concept rat-heart study combined panoramic hyperspectral imaging with optical mapping to relate epicardial tissue composition to cardiac electrical activity. The approach identified infarct and border-zone regions and paired their structural signatures with action-potential measurements, while remaining limited by its ex vivo surface view, motion suppression, artifacts, and small sample size.
Mitochondrial ROS in TiO₂ Nanoparticle Toxicity
2026-11-19
A literature-focused analysis of how titanium dioxide nanoparticles were linked to mitochondrial oxidative stress, altered mitochondrial dynamics, metabolic reprogramming, apoptosis, and autophagy in BV2 microglial cells.
How ARS-853 Could Interrupt KRAS Signaling
2026-11-18
ARS-853 is documented as a selective covalent inhibitor associated with mutant KRAS-driven signaling. The useful interpretation is mechanistic: binding to a GDP-associated KRAS state could limit the molecular switching events that produce downstream signaling, while the available documentation does not establish a complete quantitative or cellular efficacy profile.
Phosphorylated H1 Organizes Repair at Stalled Forks
2026-11-18
A mechanistic study links S-phase phosphorylation of linker histone H1 to stronger association with fork-associated single-stranded DNA, recruitment of HPF1 and other DNA-damage-response factors, and cellular measurements consistent with a role in genome maintenance.
How a Melanocortin Agonist Signals Through MC1R
2026-11-17
[Nle4,D-Phe7]-α-MSH is described as a broad melanocortin-receptor agonist whose strongest reported binding is at MC1R. Its documented receptor profile helps explain why pigmentation is a prominent research readout, while also showing why receptor affinity alone cannot establish cellular or animal efficacy.
Deuterium-Labeled Degarelix: What the Study Shows
2026-11-17
The paper presents a synthetic chemistry proof-of-concept for introducing deuterium into the naphthalene-containing amino-acid unit of degarelix. Its evidence supports analytical isotope labeling and product characterization, while leaving biological and pharmacokinetic performance outside the study’s scope.
How G9a/GLP Inhibition Changes H3K9me2
2026-11-16
BIX 01294 is documented as a selective inhibitor of the H3K9 methyltransferases G9a and GLP. Its reported binding mode offers a mechanistic explanation for reduced H3K9me2 in several cell lines, while the accompanying toxicity finding limits how confidently that cellular readout can be interpreted as target-specific biology.
NHE1 Links Olfr2 Signaling to Atherosclerosis
2026-11-16
A mouse and macrophage study examined whether octanal-associated Olfr2 signaling promotes atherosclerotic changes through the sodium–hydrogen exchanger NHE1. The findings support a model involving altered intracellular pH, calcium- and ROS-associated responses, foam-cell formation, and NLRP3-linked inflammation, while leaving the precise molecular sequence unresolved.
How P2Y12 Blockade Changes Platelet Readouts
2026-11-15
Ticagrelor’s documented action illustrates how receptor-level antagonism can reduce ADP-amplified platelet aggregation, while also showing why an ex vivo aggregation result should not be treated as a complete measure of thrombosis or clinical benefit.
Interpreting Clofoctol’s Documented Activity
2026-11-14
What can be concluded from clofoctol’s documented antibacterial, tissue-distribution, anticancer, and antiviral claims—and where does the evidence remain qualitative?
IRP2, TFEB and Macrophage Antimicrobial Function
2026-11-13
A mouse and macrophage study links myeloid IRP2 to lysosomal acidification, TFEB localization and bacterial clearance during intestinal inflammation. The findings support a mechanistic connection involving HIF2 activity and lactic-acid metabolism, while human biopsy observations provide molecular concordance rather than evidence of treatment efficacy.
H-89 and Wnt-Driven Osteoblast Metabolism
2026-11-13
A mechanistic analysis of how H-89 informs the proposed Ca2+-PKA-GFAT1 pathway linking Wnt signaling to O-GlcNAcylation, glycolysis, and osteoblastogenesis, with emphasis on what the evidence establishes—and what it cannot prove.
Super-Resolution Maps Organelle Proximity
2026-11-12
A methods-focused study shows how Airyscan and structured illumination microscopy, paired with feature-based pixel classification, can improve the structural representation and quantitative analysis of organelles in living cells. The workflow strengthens morphology-based comparisons but does not, by itself, establish molecular tethering or direct nanoscale contact distances.
From RAR Agonism to Cellular Readouts
2026-11-12
How the documented identity of adapalene sodium salt as a synthetic retinoid and RAR agonist supports a mechanistic interpretation—and where that interpretation stops short of product-specific efficacy.
How Umeclidinium Links Receptors to Calcium Flux
2026-11-11
Umeclidinium bromide, also identified as GSK573719A, is documented as a high-affinity antagonist at human muscarinic receptors. Its binding measurements and inhibition of acetylcholine-evoked calcium signals support receptor-level interruption of muscarinic signaling, while remaining distinct from direct evidence of airway dilation or clinical COPD benefit.